The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Physiology and Pharmacology of Erythropoietin
Open accessAbstract
Human erythropoietin (Epo) is a 30.4 kDa glycoprotein hormone composed of a single 165 amino acid residues chain to which four glycans are attached. The kidneys are the primary sources of Epo, its synthesis is controlled by hypoxia-inducible transcription factors (HIFs). Epo is an essential factor for the viability and proliferation of erythrocytic progenitors. Whether Epo exerts cytoprotection outside the bone marrow still needs to be clarified. Epo deficiency is the primary cause of the anemia in chronic kidney disease (CKD). Treatment with recombinant human Epo (rhEpo, epoetin) can be beneficial not only in CKD but also for other indications, primarily anemia in cancer patients receiving chemotherapy. Considering unwanted events, the administration of rhEpo or its analogs may increase the incidence of thromboembolism. The expiry of the patents for the original epoetins has initiated the production of similar biological medicinal products (‘biosimilars'). Furthermore, analogs (darbepoetin alfa, methoxy PEG-epoetin beta) with prolonged survival in circulation have been developed (‘biobetter'). New erythropoiesis-stimulating agents are in clinical trials. These include compounds that augment erythropoiesis directly (e.g. Epo mimetic peptides or activin A binding protein) and chemicals that act indirectly by stimulating endogenous Epo synthesis (HIF stabilizers).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke
Ehrenreich, H., Weissenborn, K., Prange, H., Schneider, D., Weimar, C., Wartenberg, K., Schellinger, P. D., Bohn, M., Becker, H., Wegrzyn, M., et al. (2009) · Stroke · doi:10.1161/strokeaha.109.564872 · Cited by 605
Detection, evaluation, and management of iron-restricted erythropoiesis
Goodnough, L. T., Nemeth, E., & Ganz, T. (2010) · Blood · doi:10.1182/blood-2010-05-286260 · Cited by 410
Hypoxic regulation of erythropoiesis and iron metabolism
Haase, V. H. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00174.2010 · Cited by 347
Cloning of the human erythropoietin receptor gene
Noguchi, C. T., Bae, K., Chin, K., Wada, Y., Schechter, A., & Hankins, W. D. (1991) · Blood · doi:10.1182/blood.v78.10.2548.2548 · Cited by 87
Masuda, S., Nagao, M., & Sasaki, R. (1999) · PubMed · Cited by 71
Cited by
Anemia: progress in molecular mechanisms and therapies
Sankaran, V. G., & Weiss, M. J. (2015) · Nature Medicine · doi:10.1038/nm.3814 · Cited by 281
A Photo‐Crosslinkable Kidney ECM‐Derived Bioink Accelerates Renal Tissue Formation
Ali, M., PR, A. K., Yoo, J. J., Zahran, F., Atala, A., & Lee, S. J. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201800992 · Cited by 264
Harlow, C. E., Gandawijaya, J., Bamford, R. A., Martin, E.-R., Wood, A. R., van der Most, P. J., Tanaka, T., Leonard, H. L., Etheridge, A. S., Innocenti, F., et al. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.08.004 · Cited by 13
Metadata
- Authors
- Jelkmann, W.
- Venue
- Transfusion Medicine and Hemotherapy
- Publisher
- S. Karger AG
- Published
- 2013
- Volume
- 40
- Issue
- 5
- Pages
- 302-309
- ISSN
- 1660-3796 (ISSN-L)
- 1660-3818
- OpenAlex
- W1986436077
- Cited by
- 273
- References
- 5
- FWCI
- 11.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Physiology and Pharmacology of Erythropoietin. https://app.cochat.ai/papers/10.1159/000356193
- The paper
- Jelkmann, W. (2013). Physiology and Pharmacology of Erythropoietin. Transfusion Medicine and Hemotherapy. https://doi.org/10.1159/000356193
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.